Beam Therapeutics | LinkedIn (original) (raw)
Biotechnology Research
Cambridge, Massachusetts 67,882 followers
Our vision is to provide life-long cures for patients suffering from serious diseases.
About us
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
Industry
Biotechnology Research
Company size
501-1,000 employees
Headquarters
Cambridge, Massachusetts
Type
Public Company
Founded
2017
Specialties
gene therapy, base editing, gene editing, precision medicines, CRISPR, CRISPR Cas9, genetic diseases, rare diseases, hematology, lipid nanoparticles, LNP, vector production, AAV, In vivo, ex vivo, Liver, mRNA Production, mRNA, DNA, RNA, Cas9, drug development, drug delivery, immunology, formulation development, virology, viral delivery, nanoparticles formulation, structural biology, cell biology, protein sciences, and cell therapy
Locations
Employees at Beam Therapeutics
Updates
- Curious how base editing works? Check out our animation and learn how the #BeamTeam is tackling diseases one letter at a time! #DaretoBeam
- This morning, Beam announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at ASTCT and CIBMTR taking place February 12 – 15, 2025, in Honolulu, Hawaii. Learn more here: https://lnkd.in/d5nwVY2m #BeamTeam #DaretoBeam
- Today, Beam announced progress across our hematology and genetic disease franchises and provided updates on anticipated upcoming milestones. Read the full update here: https://lnkd.in/eY7Vhz53 #BeamTeam #DaretoBeam #JPM25Beam will present and discuss pipeline and business updates during a presentation at the 43rd Annual J.P. Morgan Healthcare Conference today, Monday, January 13, 2025, at 1:30 p.m. PT. A live webcast will be available in the investor section of the company’s website.
- John Evans, chief executive officer of Beam, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 p.m. PT in San Francisco. A live webcast will be available in the investor section of the company's website https://lnkd.in/ej4z5M_S #DaretoBeam #BeamTeam #JPM
- Today, new data for the Engineered Stem Cell Antibody Evasion (ESCAPE) conditioning platform were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting. The data demonstrated that conditioning with a monoclonal antibody successfully achieved long-term engraftment of base edited stem cells and induced robust levels of fetal hemoglobin. Read the full press release here: https://lnkd.in/eqzpKXRS #DaretoBeam #BeamTeam #ASH24
- Today, new safety and efficacy data from the BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease were featured today in the press program for the 66th American Society of Hematology (ASH) Annual Meeting and will be presented in an oral session on Sunday, Dec. 8, 2024, at 10 a.m. PT. Read the full update here: https://lnkd.in/egH4VkmY #DaretoBeam #BeamTeam #ASH24Beam will host a live and webcast investor event on Dec. 8 at 8:00 p.m. PT to review the key presentations from this year’s ASH meeting. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section Beam’s website.
Join now to see what you are missing
Similar pages
- Tessera Therapeutics Biotechnology Research Somerville, MA
- Intellia Therapeutics, Inc. Biotechnology Research Cambridge, Massachusetts
- Verve Therapeutics Biotechnology Research Boston, Massachusetts
- Sarepta Therapeutics Biotechnology Research Cambridge, MA
- Vertex Pharmaceuticals Biotechnology Research Boston, MA
- Alnylam Pharmaceuticals Biotechnology Research Cambridge, Massachusetts
- Kymera Therapeutics Biotechnology Research Watertown, MA
- Sage Therapeutics Biotechnology Research Cambridge, MA
- Allogene Therapeutics Biotechnology South San Francisco, California
- Orna Therapeutics Biotechnology Research Watertown, Massachusetts
Browse jobs
- Scientist jobs 48,969 open jobs
- Manager jobs 1,880,925 open jobs
- Director jobs 1,220,357 open jobs
- Associate Scientist jobs 19,864 open jobs
- Project Manager jobs 253,048 open jobs
- Principal Scientist jobs 11,010 open jobs
- Clinical Research jobs 103,468 open jobs
- Specialist jobs 768,666 open jobs
- Associate jobs 1,091,945 open jobs
- Research Assistant jobs 43,677 open jobs
- Clinical Trial Associate jobs 6,629 open jobs
- Clinical Trial Manager jobs 4,687 open jobs
- Intern jobs 71,196 open jobs
- Vice President jobs 235,270 open jobs
- Senior Vice President jobs 16,318 open jobs
- Associate Director jobs 125,209 open jobs
- Vice President Marketing jobs 11,647 open jobs
- Analyst jobs 694,057 open jobs
- Quality Specialist jobs 40,400 open jobs
- Head of Sales jobs 12,761 open jobs